What benefits did aspirin show in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-A) trial?
The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-A) trial compared aspirin plus clopidogrel vs aspirin monotherapy among patients in whom VKA was The study found a decrease in risk of stroke with dual antiplatelet therapy (DAPT), but the major bleeding rates with aspirin-clopidogrel were comparable to rates seen with warfarin (approximately 2% per year).